U.S. markets closed

Ocuphire Pharma, Inc. (OCUP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
4.8300+0.0700 (+1.47%)
At close: 4:00PM EDT
4.9300 +0.10 (2.07%)
After hours: 05:29PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Triple Moving Average Crossover

Triple Moving Average Crossover

Previous Close4.7600
Open4.7000
Bid4.8400 x 1000
Ask4.9000 x 2900
Day's Range4.6800 - 4.9300
52 Week Range3.6800 - 13.8100
Volume279,260
Avg. Volume500,689
Market Cap75.546M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateAug 12, 2021 - Aug 16, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est23.50
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Ocuphire Pharma: Keep Your Eye on this Stock
    TipRanks

    Ocuphire Pharma: Keep Your Eye on this Stock

    Ocuphire Pharma (OCUP) is a biopharmaceutical company that operates at the clinical stage. Its primary focus is developing and selling eye disorder therapies. The main value for OCUP comes from its pipeline of highly potential therapies which the company hopes will turn into massive cash flow streams in the future. Its leading candidate at the moment is Nyxol eye drops, which are in Phase 3 clinical trials. These drops have the potential to help with dim light and night vision disturbances as we

  • PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117
    GlobeNewswire

    PROCESSA PHARMACEUTICALS ENTERS INTO A LICENSING AGREEMENT WITH OCUPHIRE PHARMA, INC., FOR THE DEVELOPMENT OF RX-3117

    HANOVER, MD, June 17, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA) announced today that it has entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs. Rx-3117 has a family of patents extending into 2036 as well as U.S. Food and Drug Administration (FDA) Orphan Designation for the treatment of Panc

  • Ocuphire Announces Addition to the Russell Microcap® Index
    GlobeNewswire

    Ocuphire Announces Addition to the Russell Microcap® Index

    FARMINGTON HILLS, Mich., June 11, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on development and commercialization of therapies for the treatment of several eye disorders, today announced that the Company is set to join the Russell Microcap® Index at the conclusion of the 2021 Russell indexes annual reconstitution, effective after the US market opens on June 28, 2021, according to a preliminary list of additions pos